# Larry Norton

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/larry-norton/

## Facts

| Field | Value |
| --- | --- |
| Citations | 91,156 |
| Field | Breast Cancer Treatment Studies |
| h-index | 133 |
| i10-index | 446 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5039225060 |
| ORCID iD | 0000-0003-3701-9250 |
| Works | 1,058 |

## Researcher papers

Showing 12 of 25.

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer](https://scholariq.org/papers/american-society-of-clinical-oncology-2007-update-of-recommendations-for-the-use/)
- [Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.](https://scholariq.org/papers/polychemotherapy-for-early-breast-cancer-an-overview-of-the-randomised-trials/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women](https://scholariq.org/papers/the-effect-of-raloxifene-on-risk-of-breast-cancer-in-postmenopausal-women/)
- [A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-letrozole-in-postmenopausal-women-after-five-years-of/)
- [The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress](https://scholariq.org/papers/the-memorial-symptom-assessment-scale-an-instrument-for-the-evaluation-of/)
- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.](https://scholariq.org/papers/phase-ii-study-of-weekly-intravenous-recombinant-humanized-anti-p185her2/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.